Search...

⌘K

Try AI Medical Scribe

Save 2+ hours daily with instant clinal dicumentation.

Start Free Trial

ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC

ASCVD Risk Calculator

Estimates 10-year and lifetime risk of atherosclerotic cardiovascular disease

ASCVD (Atherosclerotic Cardiovascular Disease) 2013 Risk Calculator from AHA/ACC

ASCVD Risk Calculator

Estimates 10-year and lifetime risk of atherosclerotic cardiovascular disease

Sex
Race
African American or White or Other
Age
Patient age in years
years
Total Cholesterol
Total cholesterol level
mg/dL
HDL Cholesterol
HDL cholesterol level
mg/dL
Systolic Blood Pressure
Systolic BP
mmHg
Treatment for High Blood Pressure
Diabetes
Smoker
10-Year ASCVD Risk Enter all values
0/9 answered · enter values to update (0-100)

Instructions

The ASCVD (Atherosclerotic Cardiovascular Disease) Risk Calculator estimates the 10-year risk of developing cardiovascular events such as myocardial infarction or stroke in adults aged 40–79 years. It uses patient demographics and clinical factors including age, sex, race, cholesterol levels, blood pressure, diabetes status, smoking history, and treatment status for cholesterol or hypertension. Clinicians enter this data, and the calculator provides a risk percentage that helps guide preventive measures, including lifestyle modification and statin therapy.

Overview
When to use
Why use
Evidences

Interpretation

10-Year ASCVD Risk (%)

Risk Category

< 5%

Low Risk

5% – 7.4%

Borderline Risk

7.5% – 19.9%

Intermediate Risk

≥ 20%

High Risk

The PCE were developed from multiple US cohorts including large samples of Black and White adults, incorporating age, sex, race, total and HDL cholesterol, systolic blood pressure, antihypertensive treatment, diabetes, and smoking status; early external validation in REGARDS showed good discrimination and, in the intended-treatment cohort, similar observed vs predicted 5-year risk when event capture was comprehensive

https://pmc.ncbi.nlm.nih.gov/articles/PMC4189930/

Analyses in diverse contemporary cohorts have noted overestimation in some groups and settings, particularly at higher predicted risk and among overweight/obese individuals; nonetheless, calibration tends to be acceptable near clinical decision thresholds (e.g., 7.5%) and overall discrimination remains good (C≈0.76 in a large integrated system)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772343

In an Asian primary care cohort, performance varied with some calibration concerns vs Framingham-based tools, emphasizing the need for local validation when applying PCE outside US Black/White populations

https://pmc.ncbi.nlm.nih.gov/articles/PMC4246627/

ACC/AHA guidance uses risk categories to anchor statin decisions: borderline risk (5–<7.5%) and intermediate risk (7.5–<20%) prompt consideration of risk enhancers and shared decision-making, whereas higher risk supports statin initiation; USPSTF 2022 recommends statins for adults 40–75 with ≥1 risk factor and 10-year risk ≥10%, with selective offering at 7.5–<10%.

https://pubmed.ncbi.nlm.nih.gov/36038004/

Overview
When to use
Why use
Evidences

The ASCVD Risk Calculator is a validated tool developed by the American College of Cardiology (ACC) and the American Heart Association (AHA) to improve cardiovascular disease prevention strategies. Since ASCVD remains a leading cause of morbidity and mortality worldwide, accurate risk prediction is critical for early intervention. This calculator uses pooled cohort equations, derived from diverse U.S. population cohorts, to predict a person’s 10-year risk of heart attack, coronary death, or stroke.

The tool integrates modifiable risk factors such as total cholesterol, HDL cholesterol, systolic blood pressure, diabetes status, and smoking history, along with non-modifiable variables like age, sex, and race. By producing a percentage score, it helps clinicians categorize patients into low, borderline, intermediate, or high-risk groups. This stratification allows for tailored preventive strategies, including lifestyle counseling, statin initiation, or more aggressive blood pressure management.

One of the main strengths of the ASCVD Risk Calculator is its ability to balance overtreatment and undertreatment. It supports shared decision-making by quantifying potential benefit from preventive therapy. However, limitations exist: it may overestimate risk in certain populations (e.g., those with healthier lifestyle behaviors) and underestimate risk in others (e.g., South Asians, who are often at higher risk). It also does not apply to individuals under 40 years, over 79 years, or those with established ASCVD, who require individualized management.

Overview
When to use
Why use
Evidences

Interpretation

10-Year ASCVD Risk (%)

Risk Category

< 5%

Low Risk

5% – 7.4%

Borderline Risk

7.5% – 19.9%

Intermediate Risk

≥ 20%

High Risk

The PCE were developed from multiple US cohorts including large samples of Black and White adults, incorporating age, sex, race, total and HDL cholesterol, systolic blood pressure, antihypertensive treatment, diabetes, and smoking status; early external validation in REGARDS showed good discrimination and, in the intended-treatment cohort, similar observed vs predicted 5-year risk when event capture was comprehensive

https://pmc.ncbi.nlm.nih.gov/articles/PMC4189930/

Analyses in diverse contemporary cohorts have noted overestimation in some groups and settings, particularly at higher predicted risk and among overweight/obese individuals; nonetheless, calibration tends to be acceptable near clinical decision thresholds (e.g., 7.5%) and overall discrimination remains good (C≈0.76 in a large integrated system)

https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2772343

In an Asian primary care cohort, performance varied with some calibration concerns vs Framingham-based tools, emphasizing the need for local validation when applying PCE outside US Black/White populations

https://pmc.ncbi.nlm.nih.gov/articles/PMC4246627/

ACC/AHA guidance uses risk categories to anchor statin decisions: borderline risk (5–<7.5%) and intermediate risk (7.5–<20%) prompt consideration of risk enhancers and shared decision-making, whereas higher risk supports statin initiation; USPSTF 2022 recommends statins for adults 40–75 with ≥1 risk factor and 10-year risk ≥10%, with selective offering at 7.5–<10%.

https://pubmed.ncbi.nlm.nih.gov/36038004/

Frequently Asked Questions

Features and Services FAQs

Discover the full range of features and services we offer and how to use them.

Who should not use the ASCVD Risk Calculator?+
Does a high score mean someone will definitely have a heart attack or stroke?+
Can it be used for primary prevention only?+
Does race affect results?+
Is it accurate for non-U.S. populations?+
What role do risk enhancers play?+

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

Ready to Transform Your Practice?

Join thousands of clinicians saving hours daily with AI-powered documentation.

14-day free trial • No setup fees

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.

DocScrib

AI-powered medical documentation platform revolutionizing clinical workflows through intelligent patient management and secure documentation.

© 2025 DocScrib. All rights reserved.

Model for End-Stage Liver Disease (Combined MELD)